NCT02262715View on ClinicalTrials.gov

A Study to Assess the Drug-Drug Interaction Between VX-787 and Oseltamivir

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Healthy
Interventions
DRUG

VX-787

Participants will receive VX-787, 600 mg either two times a day or once a day in either of the Part.

DRUG

Oseltamivir

Participants will receive Oseltamivir 75 mg either two times a day or once a day in either of the Part.

OTHER

Placebo

Participants will receive placebo matching to VX-787 either two times a day or or once a day.

Trial Locations (1)

Unknown

Merksem

All Listed Sponsors
lead

Janssen Infectious Diseases BVBA

INDUSTRY

NCT02262715 - A Study to Assess the Drug-Drug Interaction Between VX-787 and Oseltamivir | Biotech Hunter | Biotech Hunter